跳至主要内容
临床试验/EUCTR2012-003943-32-DE
EUCTR2012-003943-32-DE进行中(未招募)1 期

Influence of diabetes control on treatment of diabetic macular edema with ranibizumab

Charité University Medicine Berlin0 个研究点目标入组 120 人开始时间: 2015年3月31日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Patients with diabetic macular edema relevant to visual acuity
  • -OCT retinal thickness >= 250µm
  • -HbA1c > 6,5% at initial visit
  • -BCVA <= 0.8 and >= 0,05
  • -Age >= 18 years
  • -Written informed consent given
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 40

排除标准

  • -Previous treatment with intravitreal drugs in last 6 months
  • -Vitreous hemorrhage as a consequence of proliferative retinopathy which would hamper adequate diagnosis and imaging
  • -Blood pressure of >= 180/100 (or uncontrolled pressures under pharmacological therapy)
  • -Chronic systemic or ocular inflammatory/autoimmune diseases (e.g. inflammatory bowel disease, Addison´s disease, Cushing Syndrome, Uveitis)
  • -Systemic cortisone or anti-VEGF therapy
  • -Acute systemic or ocular infectious diseases
  • -Prior laser photocoagulation treatment within 3 months (focal / grid laser or panretinal) prior to study entry
  • -Current treatment with pharmaceutical preparations with which interactions can be expected
  • -Persons who have a fluorescein allergy
  • -Women who are pregnant or breast feeding

研究者

相似试验